Cns Pharmaceuticals, Inc. CNSP
We take great care to ensure that the data presented and summarized in this overview for CNS Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNSP
View allLatest Institutional Activity in CNSP
Top Purchases
Top Sells
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Insider Transactions at CNSP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2024
|
John M Climaco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
166,666
+43.59%
|
$0
$0.3 P/Share
|
|
Feb 01
2024
|
Christopher Downs Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
66,666
+39.19%
|
$0
$0.3 P/Share
|
|
Feb 01
2024
|
Carl Anthony Evans Director |
BUY
Open market or private purchase
|
Direct |
33,333
+49.91%
|
$0
$0.3 P/Share
|
|
Feb 01
2024
|
Jerzy Gumulka Director |
BUY
Open market or private purchase
|
Direct |
33,333
+43.66%
|
$0
$0.3 P/Share
|
|
Aug 22
2023
|
Christopher Downs Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
27,000
+42.34%
|
$27,000
$1.27 P/Share
|
|
Aug 16
2023
|
John M Climaco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,750
+5.31%
|
$2,750
$1.8 P/Share
|
|
Apr 28
2023
|
Christopher Downs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+5.06%
|
-
|
|
Apr 28
2023
|
John M Climaco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+2.63%
|
-
|
|
Apr 19
2023
|
Jerzy Gumulka Director |
BUY
Open market or private purchase
|
Direct |
2,500
+20.54%
|
$2,500
$1.7 P/Share
|
|
Apr 17
2023
|
Christopher Downs Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,100
+25.1%
|
$9,300
$3.2 P/Share
|
|
Apr 12
2023
|
John M Climaco Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+25.0%
|
$0
$0.69 P/Share
|
|
Apr 10
2023
|
Jerzy Gumulka Director |
BUY
Open market or private purchase
|
Direct |
7,173
+50.0%
|
$0
$0.74 P/Share
|
|
Mar 28
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
10,000
-6.0%
|
$10,000
$1.04 P/Share
|
|
Mar 27
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.91%
|
$5,000
$1.09 P/Share
|
|
Mar 24
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.83%
|
$5,000
$1.08 P/Share
|
|
Mar 23
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
10,000
-5.35%
|
$10,000
$1.08 P/Share
|
|
Mar 22
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.61%
|
$5,000
$1.08 P/Share
|
|
Mar 21
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.54%
|
$5,000
$1.1 P/Share
|
|
Mar 20
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.48%
|
$5,000
$1.08 P/Share
|
|
Mar 17
2023
|
Waldemar Priebe |
SELL
Open market or private sale
|
Indirect |
5,000
-2.42%
|
$5,000
$1.13 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 300K shares |
|---|